Observe Medical Asa · OSL:OBSRV
Observe Medical Asa — Investor Presentation (October 2025)
18 slides from Observe Medical Asa's investor presentation, Oct 7, 2025
Slide 1: Company presentation with trading update
Company presentation with trading update 7 October 2025 Jørgen Mann, CEO
Slide 2: Disclaimer (1/2)
Disclaimer (1/2) THIS PRESENTATION IS NOT FOR PUBLICATION NOR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA OR THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATED AND THE DISTRICT OF COLUMBIA) OR ANY OTHER JURISDICTIO
Slide 3: Disclaimer (2/2)
Disclaimer (2/2) This Presentation is intended to present background information on the Company and its business and is not intended to provide complete disclosure upon which an investment decision could be made. Should the Company choose to pursue an offering of its securities in Norway or elsewher
Slide 4: Who, how and why
WHO, HOW AND WHY
Slide 5: Strategic Vision: Nordic Medtech Platform
Strategic Vision: Nordic Medtech Platform Scalable and profitable growth, product development, regulatory performance and effective manufacturing Proprietary Platform for innovative Growth & products Nordic ecosystem Optimisation Start-ups with limited access to Explore M&A and integration Commercia
Slide 6: Observe Medical: Nordic medtech company with global reach
Observe Medical Nordic medtech company with global reach Strong Medtech Portfolio UnoMeter family Biim Distribution and M&A Opportunities Scalable Platform Manufacturing Product Development Sales & Distribution Quality & Regulatory 6
Slide 7: Execution
Execution 2025 YTD 2022 2020-2021 Acquisition of Biim Ultrasound Execution Focus on launching Sippi® in selected • First major delivery of Biim • Sales to 44 countries products to Fresenius Medical markets Care • UnoMeter growth of 61% half year • Nordic distribution • Regulatory upgrade of Sippi® t
Slide 8: Trading update
TRADING UPDATE
Slide 9: Global presence established – growth to follow distributor tender wins
Global presence established – growth to follow distributor tender wins 12 month rolling order intake 25.023 TNOK approximately 21.081 21.869 21.729 20.142 19.536 19.779 18.462 18.168 14.239 17.533 17.299 15.468 15.308 14.235 15.216 13.342 12.757 11.961 9.699 8.030 5.670 5.368 4.094 1.766 1.756 14 58
Slide 10: Solid global momentum
Solid global momentum 10+ orders 5-9 orders Sweden Estonia Netherlands Spain France Switzerland Czech Republic Italy Latvia UAE Germany Poland Portugal Lithuania UK Ireland Singapore 91% Geographical coverage of Croatia Denmark Thailand Hungary Austria Belgium Vietnam Finland the historic ~360 MNOK
Slide 11: Product development and roadmap
PRODUCT DEVELOPMENT AND ROADMAP
Slide 12: The unmet challenge in intensive care..
The unmet challenge in intensive care.. CAUTI – catheter Manual Suboptimal Unnecessary 1 2 measurement 3 measurement 4 staff time associated urinary track infection inaccuracy frequency expenditure CAUTI accounting for >40% Depending on severity, contributing between $1,700 292 staff hours per ICU o
Slide 13: Preparations for launch of UnoMeter Safeti MAX
Preparations for launch of UnoMeter Safeti MAX • We use technology developed for Sippi, protected by several patents to reduce risks related to CAUTI – catheter associated urinary infection. • Production capacity is established, and we are able to start the production of UnoMeter MAX tomorrow • Pilo
Slide 14: UnoMeter Sippi® - next generation
UnoMeter Sippi® - next generation Addressing key burdens of current clinical practice, A unique, automated, digital urine meter with wireless representing considerable added value and cost savings data transfer and biofilm control Burdens of current Patient welfare: Data accuracy: Health economics:
Slide 15: Taking the position as global leader in Urine Output Measurement
Taking the position as global leader in Urine Output Measurement Upsell Sippi and Safeti Max to existing Expand portfolio to Recapture the market through UnoMeter family of products clients at higher price points and better allow access to full margins market potential UnoMeter 500 Abdo-Pressure Uno
Slide 16: Meeting the challenge in intensive care
Meeting the challenge in intensive care CAUTI – catheter Manual Suboptimal Unnecessary 1 2 measurement 3 measurement 4 staff time associated urinary track infection inaccuracy frequency expenditure CAUTI accounting for >40% Depending on severity, contributing between $1,700 292 staff hours per ICU o
Slide 17: Innovation pipeline drives market to NOK 4 billion
Innovation pipeline drives market to NOK 4 billion Current market value for manual systems NOK 1.5 bn Sippi® ✓ Current global market potential 679 1.548 ✓ Upsell Sippi to existing customers at higher 870 price points and better margins ✓ Sales generated through sales of Base units and disposable sys
Slide 18: Q&A
Q&A Keone
Observe Medical — Investor Presentation (October 2025) on 6ix